Skip to content

Chemomab Therapeutics Ltd.

CMMB

CIK 0001534248

← back to feed
Revenue (TTM)
—
FY Dec 2025
Net Income (TTM)
−$12.88M
+35.5% YoY FY Dec 2025
EPS Diluted (TTM)
$0.12
−53.8% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
—
FY Dec 2025
Net Margin
—
FY Dec 2025
Free Cash Flow (TTM)
−$14.13M
FY Dec 2025
Cash
$7.56M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
575.38M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings